nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—KCNH2—Sunitinib—pancreatic cancer	0.0365	0.0761	CbGbCtD
Aripiprazole—CYP3A7—Tamoxifen—pancreatic cancer	0.0333	0.0695	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.0333	0.0695	CbGbCtD
Aripiprazole—CYP3A7—Irinotecan—pancreatic cancer	0.0256	0.0533	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.0256	0.0533	CbGbCtD
Aripiprazole—CYP3A5—Tamoxifen—pancreatic cancer	0.025	0.0521	CbGbCtD
Aripiprazole—CYP3A5—Erlotinib—pancreatic cancer	0.0213	0.0443	CbGbCtD
Aripiprazole—CYP3A5—Irinotecan—pancreatic cancer	0.0192	0.04	CbGbCtD
Aripiprazole—CYP3A7—Docetaxel—pancreatic cancer	0.0188	0.0391	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.0188	0.0391	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.0187	0.0389	CbGbCtD
Aripiprazole—CYP3A7—Sunitinib—pancreatic cancer	0.0187	0.0389	CbGbCtD
Aripiprazole—ABCB1—Tamoxifen—pancreatic cancer	0.0163	0.0339	CbGbCtD
Aripiprazole—CYP2D6—Tamoxifen—pancreatic cancer	0.0153	0.032	CbGbCtD
Aripiprazole—CYP3A5—Docetaxel—pancreatic cancer	0.0141	0.0293	CbGbCtD
Aripiprazole—ABCB1—Gemcitabine—pancreatic cancer	0.014	0.0292	CbGbCtD
Aripiprazole—CYP3A5—Sunitinib—pancreatic cancer	0.014	0.0292	CbGbCtD
Aripiprazole—ABCB1—Erlotinib—pancreatic cancer	0.0138	0.0288	CbGbCtD
Aripiprazole—CYP2D6—Erlotinib—pancreatic cancer	0.013	0.0272	CbGbCtD
Aripiprazole—HTR3A—enteric nervous system—pancreatic cancer	0.0128	0.33	CbGeAlD
Aripiprazole—ABCB1—Irinotecan—pancreatic cancer	0.0125	0.026	CbGbCtD
Aripiprazole—CYP3A4—Tamoxifen—pancreatic cancer	0.00975	0.0203	CbGbCtD
Aripiprazole—ABCB1—Docetaxel—pancreatic cancer	0.00915	0.0191	CbGbCtD
Aripiprazole—ABCB1—Sunitinib—pancreatic cancer	0.00911	0.019	CbGbCtD
Aripiprazole—CYP3A4—Erlotinib—pancreatic cancer	0.00829	0.0173	CbGbCtD
Aripiprazole—HTR7—enteric nervous system—pancreatic cancer	0.00828	0.213	CbGeAlD
Aripiprazole—CYP3A4—Irinotecan—pancreatic cancer	0.00748	0.0156	CbGbCtD
Aripiprazole—ABCB1—Doxorubicin—pancreatic cancer	0.00682	0.0142	CbGbCtD
Aripiprazole—CYP2D6—Doxorubicin—pancreatic cancer	0.00643	0.0134	CbGbCtD
Aripiprazole—CYP3A4—Docetaxel—pancreatic cancer	0.00548	0.0114	CbGbCtD
Aripiprazole—CYP3A4—Sunitinib—pancreatic cancer	0.00546	0.0114	CbGbCtD
Aripiprazole—HTR2A—enteric nervous system—pancreatic cancer	0.00516	0.133	CbGeAlD
Aripiprazole—CYP3A4—Doxorubicin—pancreatic cancer	0.00409	0.00852	CbGbCtD
Aripiprazole—H1F0—islet of Langerhans—pancreatic cancer	0.00128	0.033	CbGeAlD
Aripiprazole—HTR3A—islet of Langerhans—pancreatic cancer	0.00122	0.0315	CbGeAlD
Aripiprazole—H1F0—pancreas—pancreatic cancer	0.000901	0.0232	CbGeAlD
Aripiprazole—H1F0—digestive system—pancreatic cancer	0.00077	0.0198	CbGeAlD
Aripiprazole—KCNH2—islet of Langerhans—pancreatic cancer	0.000737	0.019	CbGeAlD
Aripiprazole—HTR3A—digestive system—pancreatic cancer	0.000734	0.0189	CbGeAlD
Aripiprazole—CYP3A5—islet of Langerhans—pancreatic cancer	0.000609	0.0157	CbGeAlD
Aripiprazole—ADRA2A—islet of Langerhans—pancreatic cancer	0.00058	0.015	CbGeAlD
Aripiprazole—SLC6A4—digestive system—pancreatic cancer	0.00056	0.0144	CbGeAlD
Aripiprazole—HTR2B—digestive system—pancreatic cancer	0.000555	0.0143	CbGeAlD
Aripiprazole—ADRA2C—pancreas—pancreatic cancer	0.000511	0.0132	CbGeAlD
Aripiprazole—CHRM3—digestive system—pancreatic cancer	0.000499	0.0129	CbGeAlD
Aripiprazole—HTR7—digestive system—pancreatic cancer	0.000475	0.0122	CbGeAlD
Aripiprazole—CYP3A5—pancreas—pancreatic cancer	0.000428	0.011	CbGeAlD
Aripiprazole—ADRA2A—pancreas—pancreatic cancer	0.000408	0.0105	CbGeAlD
Aripiprazole—CYP3A5—digestive system—pancreatic cancer	0.000365	0.00942	CbGeAlD
Aripiprazole—HRH1—digestive system—pancreatic cancer	0.000355	0.00914	CbGeAlD
Aripiprazole—ABCB1—islet of Langerhans—pancreatic cancer	0.000323	0.00833	CbGeAlD
Aripiprazole—HTR2A—digestive system—pancreatic cancer	0.000296	0.00763	CbGeAlD
Aripiprazole—CYP3A4—digestive system—pancreatic cancer	0.000274	0.00707	CbGeAlD
Aripiprazole—CYP2D6—digestive system—pancreatic cancer	0.00027	0.00695	CbGeAlD
Aripiprazole—ABCB1—pancreas—pancreatic cancer	0.000227	0.00586	CbGeAlD
Aripiprazole—ABCB1—digestive system—pancreatic cancer	0.000194	0.005	CbGeAlD
Aripiprazole—Pruritus—Gemcitabine—pancreatic cancer	6.64e-05	0.000225	CcSEcCtD
Aripiprazole—Infection—Docetaxel—pancreatic cancer	6.62e-05	0.000224	CcSEcCtD
Aripiprazole—Weight decreased—Doxorubicin—pancreatic cancer	6.62e-05	0.000224	CcSEcCtD
Aripiprazole—Sinusitis—Epirubicin—pancreatic cancer	6.61e-05	0.000224	CcSEcCtD
Aripiprazole—Hyperglycaemia—Doxorubicin—pancreatic cancer	6.6e-05	0.000223	CcSEcCtD
Aripiprazole—Diarrhoea—Irinotecan—pancreatic cancer	6.6e-05	0.000223	CcSEcCtD
Aripiprazole—Agranulocytosis—Epirubicin—pancreatic cancer	6.58e-05	0.000222	CcSEcCtD
Aripiprazole—Pneumonia—Doxorubicin—pancreatic cancer	6.56e-05	0.000222	CcSEcCtD
Aripiprazole—Shock—Docetaxel—pancreatic cancer	6.56e-05	0.000222	CcSEcCtD
Aripiprazole—Nervous system disorder—Docetaxel—pancreatic cancer	6.54e-05	0.000221	CcSEcCtD
Aripiprazole—Pruritus—Fluorouracil—pancreatic cancer	6.53e-05	0.000221	CcSEcCtD
Aripiprazole—Thrombocytopenia—Docetaxel—pancreatic cancer	6.53e-05	0.000221	CcSEcCtD
Aripiprazole—Infestation NOS—Doxorubicin—pancreatic cancer	6.52e-05	0.000221	CcSEcCtD
Aripiprazole—Infestation—Doxorubicin—pancreatic cancer	6.52e-05	0.000221	CcSEcCtD
Aripiprazole—Tachycardia—Docetaxel—pancreatic cancer	6.5e-05	0.00022	CcSEcCtD
Aripiprazole—Skin disorder—Docetaxel—pancreatic cancer	6.47e-05	0.000219	CcSEcCtD
Aripiprazole—Bradycardia—Epirubicin—pancreatic cancer	6.44e-05	0.000218	CcSEcCtD
Aripiprazole—Diarrhoea—Gemcitabine—pancreatic cancer	6.43e-05	0.000217	CcSEcCtD
Aripiprazole—Renal failure—Doxorubicin—pancreatic cancer	6.41e-05	0.000217	CcSEcCtD
Aripiprazole—Neuropathy peripheral—Doxorubicin—pancreatic cancer	6.39e-05	0.000216	CcSEcCtD
Aripiprazole—Dizziness—Irinotecan—pancreatic cancer	6.38e-05	0.000216	CcSEcCtD
Aripiprazole—Haemoglobin—Epirubicin—pancreatic cancer	6.36e-05	0.000215	CcSEcCtD
Aripiprazole—Stomatitis—Doxorubicin—pancreatic cancer	6.36e-05	0.000215	CcSEcCtD
Aripiprazole—Jaundice—Doxorubicin—pancreatic cancer	6.36e-05	0.000215	CcSEcCtD
Aripiprazole—Anorexia—Docetaxel—pancreatic cancer	6.35e-05	0.000215	CcSEcCtD
Aripiprazole—Rhinitis—Epirubicin—pancreatic cancer	6.34e-05	0.000214	CcSEcCtD
Aripiprazole—Urinary tract infection—Doxorubicin—pancreatic cancer	6.34e-05	0.000214	CcSEcCtD
Aripiprazole—Conjunctivitis—Doxorubicin—pancreatic cancer	6.34e-05	0.000214	CcSEcCtD
Aripiprazole—Haemorrhage—Epirubicin—pancreatic cancer	6.33e-05	0.000214	CcSEcCtD
Aripiprazole—Hepatitis—Epirubicin—pancreatic cancer	6.33e-05	0.000214	CcSEcCtD
Aripiprazole—Diarrhoea—Fluorouracil—pancreatic cancer	6.32e-05	0.000214	CcSEcCtD
Aripiprazole—Hypoaesthesia—Epirubicin—pancreatic cancer	6.3e-05	0.000213	CcSEcCtD
Aripiprazole—Pharyngitis—Epirubicin—pancreatic cancer	6.28e-05	0.000212	CcSEcCtD
Aripiprazole—Sweating—Doxorubicin—pancreatic cancer	6.25e-05	0.000211	CcSEcCtD
Aripiprazole—Urinary tract disorder—Epirubicin—pancreatic cancer	6.25e-05	0.000211	CcSEcCtD
Aripiprazole—Oedema peripheral—Epirubicin—pancreatic cancer	6.23e-05	0.000211	CcSEcCtD
Aripiprazole—Hypotension—Docetaxel—pancreatic cancer	6.23e-05	0.000211	CcSEcCtD
Aripiprazole—Haematuria—Doxorubicin—pancreatic cancer	6.22e-05	0.00021	CcSEcCtD
Aripiprazole—Connective tissue disorder—Epirubicin—pancreatic cancer	6.22e-05	0.00021	CcSEcCtD
Aripiprazole—Urethral disorder—Epirubicin—pancreatic cancer	6.2e-05	0.00021	CcSEcCtD
Aripiprazole—Hepatobiliary disease—Doxorubicin—pancreatic cancer	6.17e-05	0.000209	CcSEcCtD
Aripiprazole—Epistaxis—Doxorubicin—pancreatic cancer	6.15e-05	0.000208	CcSEcCtD
Aripiprazole—Vomiting—Irinotecan—pancreatic cancer	6.13e-05	0.000207	CcSEcCtD
Aripiprazole—Sinusitis—Doxorubicin—pancreatic cancer	6.12e-05	0.000207	CcSEcCtD
Aripiprazole—Dizziness—Fluorouracil—pancreatic cancer	6.11e-05	0.000206	CcSEcCtD
Aripiprazole—Visual impairment—Epirubicin—pancreatic cancer	6.1e-05	0.000206	CcSEcCtD
Aripiprazole—Agranulocytosis—Doxorubicin—pancreatic cancer	6.09e-05	0.000206	CcSEcCtD
Aripiprazole—Rash—Irinotecan—pancreatic cancer	6.08e-05	0.000206	CcSEcCtD
Aripiprazole—Dermatitis—Irinotecan—pancreatic cancer	6.07e-05	0.000205	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	6.07e-05	0.000205	CcSEcCtD
Aripiprazole—Headache—Irinotecan—pancreatic cancer	6.04e-05	0.000204	CcSEcCtD
Aripiprazole—Insomnia—Docetaxel—pancreatic cancer	6.03e-05	0.000204	CcSEcCtD
Aripiprazole—Paraesthesia—Docetaxel—pancreatic cancer	5.98e-05	0.000202	CcSEcCtD
Aripiprazole—Vomiting—Gemcitabine—pancreatic cancer	5.97e-05	0.000202	CcSEcCtD
Aripiprazole—Bradycardia—Doxorubicin—pancreatic cancer	5.96e-05	0.000202	CcSEcCtD
Aripiprazole—Dyspnoea—Docetaxel—pancreatic cancer	5.94e-05	0.000201	CcSEcCtD
Aripiprazole—Somnolence—Docetaxel—pancreatic cancer	5.92e-05	0.0002	CcSEcCtD
Aripiprazole—Rash—Gemcitabine—pancreatic cancer	5.92e-05	0.0002	CcSEcCtD
Aripiprazole—Dermatitis—Gemcitabine—pancreatic cancer	5.92e-05	0.0002	CcSEcCtD
Aripiprazole—Eye disorder—Epirubicin—pancreatic cancer	5.91e-05	0.0002	CcSEcCtD
Aripiprazole—Tinnitus—Epirubicin—pancreatic cancer	5.9e-05	0.000199	CcSEcCtD
Aripiprazole—Haemoglobin—Doxorubicin—pancreatic cancer	5.88e-05	0.000199	CcSEcCtD
Aripiprazole—Headache—Gemcitabine—pancreatic cancer	5.88e-05	0.000199	CcSEcCtD
Aripiprazole—Flushing—Epirubicin—pancreatic cancer	5.87e-05	0.000199	CcSEcCtD
Aripiprazole—Cardiac disorder—Epirubicin—pancreatic cancer	5.87e-05	0.000199	CcSEcCtD
Aripiprazole—Vomiting—Fluorouracil—pancreatic cancer	5.87e-05	0.000199	CcSEcCtD
Aripiprazole—Rhinitis—Doxorubicin—pancreatic cancer	5.87e-05	0.000198	CcSEcCtD
Aripiprazole—Dyspepsia—Docetaxel—pancreatic cancer	5.87e-05	0.000198	CcSEcCtD
Aripiprazole—Hepatitis—Doxorubicin—pancreatic cancer	5.85e-05	0.000198	CcSEcCtD
Aripiprazole—Haemorrhage—Doxorubicin—pancreatic cancer	5.85e-05	0.000198	CcSEcCtD
Aripiprazole—Hypoaesthesia—Doxorubicin—pancreatic cancer	5.83e-05	0.000197	CcSEcCtD
Aripiprazole—Rash—Fluorouracil—pancreatic cancer	5.82e-05	0.000197	CcSEcCtD
Aripiprazole—Dermatitis—Fluorouracil—pancreatic cancer	5.82e-05	0.000197	CcSEcCtD
Aripiprazole—Pharyngitis—Doxorubicin—pancreatic cancer	5.81e-05	0.000196	CcSEcCtD
Aripiprazole—Decreased appetite—Docetaxel—pancreatic cancer	5.79e-05	0.000196	CcSEcCtD
Aripiprazole—Headache—Fluorouracil—pancreatic cancer	5.78e-05	0.000196	CcSEcCtD
Aripiprazole—Urinary tract disorder—Doxorubicin—pancreatic cancer	5.78e-05	0.000195	CcSEcCtD
Aripiprazole—Oedema peripheral—Doxorubicin—pancreatic cancer	5.77e-05	0.000195	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Docetaxel—pancreatic cancer	5.75e-05	0.000195	CcSEcCtD
Aripiprazole—Connective tissue disorder—Doxorubicin—pancreatic cancer	5.75e-05	0.000195	CcSEcCtD
Aripiprazole—Fatigue—Docetaxel—pancreatic cancer	5.75e-05	0.000194	CcSEcCtD
Aripiprazole—Angiopathy—Epirubicin—pancreatic cancer	5.74e-05	0.000194	CcSEcCtD
Aripiprazole—Urethral disorder—Doxorubicin—pancreatic cancer	5.74e-05	0.000194	CcSEcCtD
Aripiprazole—Nausea—Irinotecan—pancreatic cancer	5.73e-05	0.000194	CcSEcCtD
Aripiprazole—Immune system disorder—Epirubicin—pancreatic cancer	5.71e-05	0.000193	CcSEcCtD
Aripiprazole—Mediastinal disorder—Epirubicin—pancreatic cancer	5.7e-05	0.000193	CcSEcCtD
Aripiprazole—Constipation—Docetaxel—pancreatic cancer	5.7e-05	0.000193	CcSEcCtD
Aripiprazole—Pain—Docetaxel—pancreatic cancer	5.7e-05	0.000193	CcSEcCtD
Aripiprazole—Chills—Epirubicin—pancreatic cancer	5.68e-05	0.000192	CcSEcCtD
Aripiprazole—Visual impairment—Doxorubicin—pancreatic cancer	5.64e-05	0.000191	CcSEcCtD
Aripiprazole—Alopecia—Epirubicin—pancreatic cancer	5.59e-05	0.000189	CcSEcCtD
Aripiprazole—Nausea—Gemcitabine—pancreatic cancer	5.58e-05	0.000189	CcSEcCtD
Aripiprazole—Mental disorder—Epirubicin—pancreatic cancer	5.54e-05	0.000187	CcSEcCtD
Aripiprazole—Malnutrition—Epirubicin—pancreatic cancer	5.51e-05	0.000186	CcSEcCtD
Aripiprazole—Erythema—Epirubicin—pancreatic cancer	5.51e-05	0.000186	CcSEcCtD
Aripiprazole—Feeling abnormal—Docetaxel—pancreatic cancer	5.49e-05	0.000186	CcSEcCtD
Aripiprazole—Nausea—Fluorouracil—pancreatic cancer	5.48e-05	0.000185	CcSEcCtD
Aripiprazole—Eye disorder—Doxorubicin—pancreatic cancer	5.47e-05	0.000185	CcSEcCtD
Aripiprazole—Tinnitus—Doxorubicin—pancreatic cancer	5.46e-05	0.000185	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Docetaxel—pancreatic cancer	5.45e-05	0.000184	CcSEcCtD
Aripiprazole—Flushing—Doxorubicin—pancreatic cancer	5.43e-05	0.000184	CcSEcCtD
Aripiprazole—Cardiac disorder—Doxorubicin—pancreatic cancer	5.43e-05	0.000184	CcSEcCtD
Aripiprazole—Flatulence—Epirubicin—pancreatic cancer	5.43e-05	0.000184	CcSEcCtD
Aripiprazole—Tension—Epirubicin—pancreatic cancer	5.4e-05	0.000183	CcSEcCtD
Aripiprazole—Dysgeusia—Epirubicin—pancreatic cancer	5.39e-05	0.000182	CcSEcCtD
Aripiprazole—Nervousness—Epirubicin—pancreatic cancer	5.35e-05	0.000181	CcSEcCtD
Aripiprazole—Back pain—Epirubicin—pancreatic cancer	5.33e-05	0.00018	CcSEcCtD
Aripiprazole—Angiopathy—Doxorubicin—pancreatic cancer	5.31e-05	0.00018	CcSEcCtD
Aripiprazole—Muscle spasms—Epirubicin—pancreatic cancer	5.3e-05	0.000179	CcSEcCtD
Aripiprazole—Immune system disorder—Doxorubicin—pancreatic cancer	5.29e-05	0.000179	CcSEcCtD
Aripiprazole—Mediastinal disorder—Doxorubicin—pancreatic cancer	5.28e-05	0.000178	CcSEcCtD
Aripiprazole—Abdominal pain—Docetaxel—pancreatic cancer	5.27e-05	0.000178	CcSEcCtD
Aripiprazole—Body temperature increased—Docetaxel—pancreatic cancer	5.27e-05	0.000178	CcSEcCtD
Aripiprazole—Chills—Doxorubicin—pancreatic cancer	5.25e-05	0.000178	CcSEcCtD
Aripiprazole—Vision blurred—Epirubicin—pancreatic cancer	5.19e-05	0.000176	CcSEcCtD
Aripiprazole—Alopecia—Doxorubicin—pancreatic cancer	5.17e-05	0.000175	CcSEcCtD
Aripiprazole—Mental disorder—Doxorubicin—pancreatic cancer	5.13e-05	0.000173	CcSEcCtD
Aripiprazole—Ill-defined disorder—Epirubicin—pancreatic cancer	5.11e-05	0.000173	CcSEcCtD
Aripiprazole—Erythema—Doxorubicin—pancreatic cancer	5.1e-05	0.000172	CcSEcCtD
Aripiprazole—Malnutrition—Doxorubicin—pancreatic cancer	5.1e-05	0.000172	CcSEcCtD
Aripiprazole—Anaemia—Epirubicin—pancreatic cancer	5.09e-05	0.000172	CcSEcCtD
Aripiprazole—Agitation—Epirubicin—pancreatic cancer	5.06e-05	0.000171	CcSEcCtD
Aripiprazole—Flatulence—Doxorubicin—pancreatic cancer	5.02e-05	0.00017	CcSEcCtD
Aripiprazole—Tension—Doxorubicin—pancreatic cancer	5e-05	0.000169	CcSEcCtD
Aripiprazole—Dysgeusia—Doxorubicin—pancreatic cancer	4.99e-05	0.000169	CcSEcCtD
Aripiprazole—Malaise—Epirubicin—pancreatic cancer	4.97e-05	0.000168	CcSEcCtD
Aripiprazole—Nervousness—Doxorubicin—pancreatic cancer	4.95e-05	0.000167	CcSEcCtD
Aripiprazole—Vertigo—Epirubicin—pancreatic cancer	4.95e-05	0.000167	CcSEcCtD
Aripiprazole—Syncope—Epirubicin—pancreatic cancer	4.94e-05	0.000167	CcSEcCtD
Aripiprazole—Leukopenia—Epirubicin—pancreatic cancer	4.93e-05	0.000167	CcSEcCtD
Aripiprazole—Back pain—Doxorubicin—pancreatic cancer	4.93e-05	0.000167	CcSEcCtD
Aripiprazole—Hypersensitivity—Docetaxel—pancreatic cancer	4.91e-05	0.000166	CcSEcCtD
Aripiprazole—Muscle spasms—Doxorubicin—pancreatic cancer	4.9e-05	0.000166	CcSEcCtD
Aripiprazole—Palpitations—Epirubicin—pancreatic cancer	4.87e-05	0.000165	CcSEcCtD
Aripiprazole—Loss of consciousness—Epirubicin—pancreatic cancer	4.84e-05	0.000164	CcSEcCtD
Aripiprazole—Cough—Epirubicin—pancreatic cancer	4.81e-05	0.000163	CcSEcCtD
Aripiprazole—Vision blurred—Doxorubicin—pancreatic cancer	4.8e-05	0.000162	CcSEcCtD
Aripiprazole—Asthenia—Docetaxel—pancreatic cancer	4.78e-05	0.000162	CcSEcCtD
Aripiprazole—Convulsion—Epirubicin—pancreatic cancer	4.77e-05	0.000161	CcSEcCtD
Aripiprazole—Hypertension—Epirubicin—pancreatic cancer	4.76e-05	0.000161	CcSEcCtD
Aripiprazole—Ill-defined disorder—Doxorubicin—pancreatic cancer	4.73e-05	0.00016	CcSEcCtD
Aripiprazole—Pruritus—Docetaxel—pancreatic cancer	4.72e-05	0.000159	CcSEcCtD
Aripiprazole—Anaemia—Doxorubicin—pancreatic cancer	4.71e-05	0.000159	CcSEcCtD
Aripiprazole—Chest pain—Epirubicin—pancreatic cancer	4.69e-05	0.000159	CcSEcCtD
Aripiprazole—Myalgia—Epirubicin—pancreatic cancer	4.69e-05	0.000159	CcSEcCtD
Aripiprazole—Arthralgia—Epirubicin—pancreatic cancer	4.69e-05	0.000159	CcSEcCtD
Aripiprazole—Agitation—Doxorubicin—pancreatic cancer	4.68e-05	0.000158	CcSEcCtD
Aripiprazole—Anxiety—Epirubicin—pancreatic cancer	4.67e-05	0.000158	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	4.66e-05	0.000157	CcSEcCtD
Aripiprazole—Discomfort—Epirubicin—pancreatic cancer	4.63e-05	0.000157	CcSEcCtD
Aripiprazole—Malaise—Doxorubicin—pancreatic cancer	4.6e-05	0.000155	CcSEcCtD
Aripiprazole—Dry mouth—Epirubicin—pancreatic cancer	4.59e-05	0.000155	CcSEcCtD
Aripiprazole—Vertigo—Doxorubicin—pancreatic cancer	4.58e-05	0.000155	CcSEcCtD
Aripiprazole—Syncope—Doxorubicin—pancreatic cancer	4.57e-05	0.000155	CcSEcCtD
Aripiprazole—Leukopenia—Doxorubicin—pancreatic cancer	4.56e-05	0.000154	CcSEcCtD
Aripiprazole—Diarrhoea—Docetaxel—pancreatic cancer	4.56e-05	0.000154	CcSEcCtD
Aripiprazole—Confusional state—Epirubicin—pancreatic cancer	4.53e-05	0.000153	CcSEcCtD
Aripiprazole—Palpitations—Doxorubicin—pancreatic cancer	4.5e-05	0.000152	CcSEcCtD
Aripiprazole—Oedema—Epirubicin—pancreatic cancer	4.5e-05	0.000152	CcSEcCtD
Aripiprazole—Anaphylactic shock—Epirubicin—pancreatic cancer	4.5e-05	0.000152	CcSEcCtD
Aripiprazole—Loss of consciousness—Doxorubicin—pancreatic cancer	4.48e-05	0.000151	CcSEcCtD
Aripiprazole—Infection—Epirubicin—pancreatic cancer	4.47e-05	0.000151	CcSEcCtD
Aripiprazole—Cough—Doxorubicin—pancreatic cancer	4.45e-05	0.00015	CcSEcCtD
Aripiprazole—Shock—Epirubicin—pancreatic cancer	4.42e-05	0.00015	CcSEcCtD
Aripiprazole—Convulsion—Doxorubicin—pancreatic cancer	4.42e-05	0.000149	CcSEcCtD
Aripiprazole—Nervous system disorder—Epirubicin—pancreatic cancer	4.41e-05	0.000149	CcSEcCtD
Aripiprazole—Dizziness—Docetaxel—pancreatic cancer	4.41e-05	0.000149	CcSEcCtD
Aripiprazole—Thrombocytopenia—Epirubicin—pancreatic cancer	4.4e-05	0.000149	CcSEcCtD
Aripiprazole—Hypertension—Doxorubicin—pancreatic cancer	4.4e-05	0.000149	CcSEcCtD
Aripiprazole—Tachycardia—Epirubicin—pancreatic cancer	4.39e-05	0.000148	CcSEcCtD
Aripiprazole—Skin disorder—Epirubicin—pancreatic cancer	4.37e-05	0.000148	CcSEcCtD
Aripiprazole—Hyperhidrosis—Epirubicin—pancreatic cancer	4.35e-05	0.000147	CcSEcCtD
Aripiprazole—Arthralgia—Doxorubicin—pancreatic cancer	4.34e-05	0.000147	CcSEcCtD
Aripiprazole—Chest pain—Doxorubicin—pancreatic cancer	4.34e-05	0.000147	CcSEcCtD
Aripiprazole—Myalgia—Doxorubicin—pancreatic cancer	4.34e-05	0.000147	CcSEcCtD
Aripiprazole—Anxiety—Doxorubicin—pancreatic cancer	4.32e-05	0.000146	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	4.31e-05	0.000146	CcSEcCtD
Aripiprazole—Discomfort—Doxorubicin—pancreatic cancer	4.29e-05	0.000145	CcSEcCtD
Aripiprazole—Anorexia—Epirubicin—pancreatic cancer	4.28e-05	0.000145	CcSEcCtD
Aripiprazole—Dry mouth—Doxorubicin—pancreatic cancer	4.24e-05	0.000143	CcSEcCtD
Aripiprazole—Vomiting—Docetaxel—pancreatic cancer	4.24e-05	0.000143	CcSEcCtD
Aripiprazole—Rash—Docetaxel—pancreatic cancer	4.2e-05	0.000142	CcSEcCtD
Aripiprazole—Hypotension—Epirubicin—pancreatic cancer	4.2e-05	0.000142	CcSEcCtD
Aripiprazole—Dermatitis—Docetaxel—pancreatic cancer	4.2e-05	0.000142	CcSEcCtD
Aripiprazole—Confusional state—Doxorubicin—pancreatic cancer	4.19e-05	0.000142	CcSEcCtD
Aripiprazole—Headache—Docetaxel—pancreatic cancer	4.18e-05	0.000141	CcSEcCtD
Aripiprazole—Anaphylactic shock—Doxorubicin—pancreatic cancer	4.16e-05	0.000141	CcSEcCtD
Aripiprazole—Oedema—Doxorubicin—pancreatic cancer	4.16e-05	0.000141	CcSEcCtD
Aripiprazole—Infection—Doxorubicin—pancreatic cancer	4.13e-05	0.00014	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	4.1e-05	0.000138	CcSEcCtD
Aripiprazole—Shock—Doxorubicin—pancreatic cancer	4.09e-05	0.000138	CcSEcCtD
Aripiprazole—Nervous system disorder—Doxorubicin—pancreatic cancer	4.08e-05	0.000138	CcSEcCtD
Aripiprazole—Thrombocytopenia—Doxorubicin—pancreatic cancer	4.07e-05	0.000138	CcSEcCtD
Aripiprazole—Insomnia—Epirubicin—pancreatic cancer	4.07e-05	0.000137	CcSEcCtD
Aripiprazole—Tachycardia—Doxorubicin—pancreatic cancer	4.06e-05	0.000137	CcSEcCtD
Aripiprazole—Skin disorder—Doxorubicin—pancreatic cancer	4.04e-05	0.000137	CcSEcCtD
Aripiprazole—Paraesthesia—Epirubicin—pancreatic cancer	4.04e-05	0.000136	CcSEcCtD
Aripiprazole—Hyperhidrosis—Doxorubicin—pancreatic cancer	4.02e-05	0.000136	CcSEcCtD
Aripiprazole—Dyspnoea—Epirubicin—pancreatic cancer	4.01e-05	0.000136	CcSEcCtD
Aripiprazole—Somnolence—Epirubicin—pancreatic cancer	4e-05	0.000135	CcSEcCtD
Aripiprazole—Anorexia—Doxorubicin—pancreatic cancer	3.96e-05	0.000134	CcSEcCtD
Aripiprazole—Nausea—Docetaxel—pancreatic cancer	3.96e-05	0.000134	CcSEcCtD
Aripiprazole—Dyspepsia—Epirubicin—pancreatic cancer	3.96e-05	0.000134	CcSEcCtD
Aripiprazole—Decreased appetite—Epirubicin—pancreatic cancer	3.91e-05	0.000132	CcSEcCtD
Aripiprazole—Hypotension—Doxorubicin—pancreatic cancer	3.89e-05	0.000131	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Epirubicin—pancreatic cancer	3.88e-05	0.000131	CcSEcCtD
Aripiprazole—Fatigue—Epirubicin—pancreatic cancer	3.88e-05	0.000131	CcSEcCtD
Aripiprazole—Pain—Epirubicin—pancreatic cancer	3.84e-05	0.00013	CcSEcCtD
Aripiprazole—Constipation—Epirubicin—pancreatic cancer	3.84e-05	0.00013	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	3.79e-05	0.000128	CcSEcCtD
Aripiprazole—Insomnia—Doxorubicin—pancreatic cancer	3.76e-05	0.000127	CcSEcCtD
Aripiprazole—Paraesthesia—Doxorubicin—pancreatic cancer	3.73e-05	0.000126	CcSEcCtD
Aripiprazole—Dyspnoea—Doxorubicin—pancreatic cancer	3.71e-05	0.000125	CcSEcCtD
Aripiprazole—Feeling abnormal—Epirubicin—pancreatic cancer	3.7e-05	0.000125	CcSEcCtD
Aripiprazole—Somnolence—Doxorubicin—pancreatic cancer	3.7e-05	0.000125	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Epirubicin—pancreatic cancer	3.68e-05	0.000124	CcSEcCtD
Aripiprazole—Dyspepsia—Doxorubicin—pancreatic cancer	3.66e-05	0.000124	CcSEcCtD
Aripiprazole—Decreased appetite—Doxorubicin—pancreatic cancer	3.62e-05	0.000122	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	3.59e-05	0.000121	CcSEcCtD
Aripiprazole—Fatigue—Doxorubicin—pancreatic cancer	3.59e-05	0.000121	CcSEcCtD
Aripiprazole—Urticaria—Epirubicin—pancreatic cancer	3.57e-05	0.000121	CcSEcCtD
Aripiprazole—Constipation—Doxorubicin—pancreatic cancer	3.56e-05	0.00012	CcSEcCtD
Aripiprazole—Pain—Doxorubicin—pancreatic cancer	3.56e-05	0.00012	CcSEcCtD
Aripiprazole—Body temperature increased—Epirubicin—pancreatic cancer	3.55e-05	0.00012	CcSEcCtD
Aripiprazole—Abdominal pain—Epirubicin—pancreatic cancer	3.55e-05	0.00012	CcSEcCtD
Aripiprazole—Feeling abnormal—Doxorubicin—pancreatic cancer	3.43e-05	0.000116	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Doxorubicin—pancreatic cancer	3.4e-05	0.000115	CcSEcCtD
Aripiprazole—Hypersensitivity—Epirubicin—pancreatic cancer	3.31e-05	0.000112	CcSEcCtD
Aripiprazole—Urticaria—Doxorubicin—pancreatic cancer	3.3e-05	0.000112	CcSEcCtD
Aripiprazole—Abdominal pain—Doxorubicin—pancreatic cancer	3.29e-05	0.000111	CcSEcCtD
Aripiprazole—Body temperature increased—Doxorubicin—pancreatic cancer	3.29e-05	0.000111	CcSEcCtD
Aripiprazole—Asthenia—Epirubicin—pancreatic cancer	3.23e-05	0.000109	CcSEcCtD
Aripiprazole—Pruritus—Epirubicin—pancreatic cancer	3.18e-05	0.000108	CcSEcCtD
Aripiprazole—Diarrhoea—Epirubicin—pancreatic cancer	3.08e-05	0.000104	CcSEcCtD
Aripiprazole—Hypersensitivity—Doxorubicin—pancreatic cancer	3.06e-05	0.000104	CcSEcCtD
Aripiprazole—Asthenia—Doxorubicin—pancreatic cancer	2.98e-05	0.000101	CcSEcCtD
Aripiprazole—Dizziness—Epirubicin—pancreatic cancer	2.97e-05	0.000101	CcSEcCtD
Aripiprazole—Pruritus—Doxorubicin—pancreatic cancer	2.94e-05	9.95e-05	CcSEcCtD
Aripiprazole—Vomiting—Epirubicin—pancreatic cancer	2.86e-05	9.66e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Doxorubicin—pancreatic cancer	2.85e-05	9.62e-05	CcSEcCtD
Aripiprazole—Rash—Epirubicin—pancreatic cancer	2.83e-05	9.58e-05	CcSEcCtD
Aripiprazole—Dermatitis—Epirubicin—pancreatic cancer	2.83e-05	9.57e-05	CcSEcCtD
Aripiprazole—Headache—Epirubicin—pancreatic cancer	2.82e-05	9.52e-05	CcSEcCtD
Aripiprazole—Dizziness—Doxorubicin—pancreatic cancer	2.75e-05	9.3e-05	CcSEcCtD
Aripiprazole—Nausea—Epirubicin—pancreatic cancer	2.67e-05	9.03e-05	CcSEcCtD
Aripiprazole—Vomiting—Doxorubicin—pancreatic cancer	2.64e-05	8.94e-05	CcSEcCtD
Aripiprazole—Rash—Doxorubicin—pancreatic cancer	2.62e-05	8.87e-05	CcSEcCtD
Aripiprazole—Dermatitis—Doxorubicin—pancreatic cancer	2.62e-05	8.86e-05	CcSEcCtD
Aripiprazole—Headache—Doxorubicin—pancreatic cancer	2.61e-05	8.81e-05	CcSEcCtD
Aripiprazole—Nausea—Doxorubicin—pancreatic cancer	2.47e-05	8.35e-05	CcSEcCtD
Aripiprazole—DRD2—Signaling Pathways—MMP9—pancreatic cancer	3.27e-06	1.76e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—HRAS—pancreatic cancer	3.27e-06	1.76e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CTNNB1—pancreatic cancer	3.27e-06	1.76e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—TP53—pancreatic cancer	3.27e-06	1.76e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—KRAS—pancreatic cancer	3.27e-06	1.76e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—HRAS—pancreatic cancer	3.27e-06	1.76e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CTNNB1—pancreatic cancer	3.26e-06	1.75e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CCND1—pancreatic cancer	3.26e-06	1.75e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—PTEN—pancreatic cancer	3.25e-06	1.75e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	3.25e-06	1.75e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—HRAS—pancreatic cancer	3.24e-06	1.75e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	3.24e-06	1.74e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	3.24e-06	1.74e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CTNNB1—pancreatic cancer	3.23e-06	1.74e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	3.23e-06	1.74e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—TP53—pancreatic cancer	3.22e-06	1.74e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	3.22e-06	1.73e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—MYC—pancreatic cancer	3.22e-06	1.73e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	3.22e-06	1.73e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	3.22e-06	1.73e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MMP9—pancreatic cancer	3.21e-06	1.73e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—TGFB1—pancreatic cancer	3.21e-06	1.73e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	3.21e-06	1.73e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MMP9—pancreatic cancer	3.2e-06	1.73e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	3.2e-06	1.72e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	3.2e-06	1.72e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3CD—pancreatic cancer	3.2e-06	1.72e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—PTEN—pancreatic cancer	3.2e-06	1.72e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MMP9—pancreatic cancer	3.19e-06	1.72e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—PTEN—pancreatic cancer	3.19e-06	1.72e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—PIK3CA—pancreatic cancer	3.19e-06	1.72e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	3.19e-06	1.72e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	3.19e-06	1.72e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—PTEN—pancreatic cancer	3.19e-06	1.72e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	3.18e-06	1.71e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—HRAS—pancreatic cancer	3.18e-06	1.71e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	3.18e-06	1.71e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—PTEN—pancreatic cancer	3.18e-06	1.71e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MMP9—pancreatic cancer	3.16e-06	1.7e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	3.16e-06	1.7e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	3.15e-06	1.7e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—EGFR—pancreatic cancer	3.15e-06	1.7e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	3.15e-06	1.7e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—PTEN—pancreatic cancer	3.14e-06	1.69e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	3.14e-06	1.69e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	3.13e-06	1.69e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—HRAS—pancreatic cancer	3.13e-06	1.68e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	3.12e-06	1.68e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	3.12e-06	1.68e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—TP53—pancreatic cancer	3.12e-06	1.68e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—AKT1—pancreatic cancer	3.12e-06	1.68e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	3.12e-06	1.68e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—AKT1—pancreatic cancer	3.11e-06	1.67e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	3.1e-06	1.67e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—AKT1—pancreatic cancer	3.1e-06	1.67e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—TP53—pancreatic cancer	3.09e-06	1.66e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—HRAS—pancreatic cancer	3.08e-06	1.66e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—MYC—pancreatic cancer	3.08e-06	1.66e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	3.07e-06	1.65e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—AKT1—pancreatic cancer	3.07e-06	1.65e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—MYC—pancreatic cancer	3.06e-06	1.65e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	3.06e-06	1.65e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	3.06e-06	1.65e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—TYMS—pancreatic cancer	3.05e-06	1.64e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—PIK3CA—pancreatic cancer	3.04e-06	1.64e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	3.03e-06	1.63e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	3.02e-06	1.63e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—SRC—pancreatic cancer	3.02e-06	1.63e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	3.01e-06	1.62e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	3.01e-06	1.62e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—PIK3CA—pancreatic cancer	3e-06	1.62e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	3e-06	1.61e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	2.99e-06	1.61e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	2.98e-06	1.61e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	2.98e-06	1.61e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—KRAS—pancreatic cancer	2.98e-06	1.6e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	2.97e-06	1.6e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—SRC—pancreatic cancer	2.97e-06	1.6e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—SRC—pancreatic cancer	2.96e-06	1.6e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—SRC—pancreatic cancer	2.95e-06	1.59e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—HRAS—pancreatic cancer	2.95e-06	1.59e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	2.95e-06	1.59e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—SRC—pancreatic cancer	2.94e-06	1.59e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—TP53—pancreatic cancer	2.94e-06	1.58e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	2.94e-06	1.58e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	2.93e-06	1.58e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	2.93e-06	1.58e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	2.93e-06	1.58e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—SRC—pancreatic cancer	2.92e-06	1.57e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	2.92e-06	1.57e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	2.91e-06	1.57e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—STAT3—pancreatic cancer	2.91e-06	1.57e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	2.91e-06	1.57e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—NRAS—pancreatic cancer	2.9e-06	1.56e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—TP53—pancreatic cancer	2.9e-06	1.56e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	2.89e-06	1.56e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—VEGFA—pancreatic cancer	2.89e-06	1.55e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—AKT1—pancreatic cancer	2.89e-06	1.55e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—AKT1—pancreatic cancer	2.88e-06	1.55e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—VEGFA—pancreatic cancer	2.88e-06	1.55e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	2.87e-06	1.55e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—VEGFA—pancreatic cancer	2.87e-06	1.54e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—AKT1—pancreatic cancer	2.86e-06	1.54e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	2.86e-06	1.54e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—STAT3—pancreatic cancer	2.86e-06	1.54e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	2.86e-06	1.54e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—NRAS—pancreatic cancer	2.85e-06	1.54e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—STAT3—pancreatic cancer	2.85e-06	1.53e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	2.85e-06	1.53e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	2.84e-06	1.53e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—NRAS—pancreatic cancer	2.84e-06	1.53e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—VEGFA—pancreatic cancer	2.84e-06	1.53e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—STAT3—pancreatic cancer	2.84e-06	1.53e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—NRAS—pancreatic cancer	2.83e-06	1.53e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	2.83e-06	1.53e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	2.83e-06	1.52e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—HRAS—pancreatic cancer	2.81e-06	1.52e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—STAT3—pancreatic cancer	2.81e-06	1.51e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—NRAS—pancreatic cancer	2.81e-06	1.51e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	2.8e-06	1.51e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—AKT1—pancreatic cancer	2.8e-06	1.51e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	2.8e-06	1.51e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3CB—pancreatic cancer	2.79e-06	1.5e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—HRAS—pancreatic cancer	2.78e-06	1.49e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PTGS2—pancreatic cancer	2.76e-06	1.49e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—AKT1—pancreatic cancer	2.76e-06	1.49e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	2.75e-06	1.48e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—PIK3CA—pancreatic cancer	2.73e-06	1.47e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—AKT1—pancreatic cancer	2.72e-06	1.47e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	2.71e-06	1.46e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	2.71e-06	1.46e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—MYC—pancreatic cancer	2.7e-06	1.46e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	2.7e-06	1.45e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	2.7e-06	1.45e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—PIK3CA—pancreatic cancer	2.68e-06	1.44e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MYC—pancreatic cancer	2.66e-06	1.43e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MYC—pancreatic cancer	2.66e-06	1.43e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	2.66e-06	1.43e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TGFB1—pancreatic cancer	2.65e-06	1.43e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MYC—pancreatic cancer	2.65e-06	1.43e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—EGFR—pancreatic cancer	2.65e-06	1.42e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—TP53—pancreatic cancer	2.65e-06	1.42e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TGFB1—pancreatic cancer	2.64e-06	1.42e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MYC—pancreatic cancer	2.64e-06	1.42e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	2.63e-06	1.42e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TGFB1—pancreatic cancer	2.63e-06	1.42e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	2.63e-06	1.42e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	2.63e-06	1.41e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	2.62e-06	1.41e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	2.62e-06	1.41e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MYC—pancreatic cancer	2.61e-06	1.41e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—AKT1—pancreatic cancer	2.61e-06	1.4e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TGFB1—pancreatic cancer	2.61e-06	1.4e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	2.61e-06	1.4e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	2.61e-06	1.4e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PTGS2—pancreatic cancer	2.6e-06	1.4e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	2.6e-06	1.4e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	2.6e-06	1.4e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	2.6e-06	1.4e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	2.6e-06	1.4e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—EGFR—pancreatic cancer	2.6e-06	1.4e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—EGFR—pancreatic cancer	2.59e-06	1.39e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—EGFR—pancreatic cancer	2.58e-06	1.39e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—EGFR—pancreatic cancer	2.56e-06	1.38e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	2.55e-06	1.37e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—AKT1—pancreatic cancer	2.55e-06	1.37e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	2.53e-06	1.36e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TP53—pancreatic cancer	2.53e-06	1.36e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—HRAS—pancreatic cancer	2.53e-06	1.36e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TP53—pancreatic cancer	2.52e-06	1.36e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	2.51e-06	1.35e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—KRAS—pancreatic cancer	2.5e-06	1.35e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	2.49e-06	1.34e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—AKT1—pancreatic cancer	2.48e-06	1.34e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—APOE—pancreatic cancer	2.48e-06	1.34e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—AKT1—pancreatic cancer	2.47e-06	1.33e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	2.46e-06	1.32e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	2.46e-06	1.32e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—KRAS—pancreatic cancer	2.45e-06	1.32e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—AKT1—pancreatic cancer	2.45e-06	1.32e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	2.45e-06	1.32e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—KRAS—pancreatic cancer	2.45e-06	1.32e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—KRAS—pancreatic cancer	2.44e-06	1.31e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	2.42e-06	1.3e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	2.42e-06	1.3e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	2.42e-06	1.3e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—KRAS—pancreatic cancer	2.41e-06	1.3e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PTEN—pancreatic cancer	2.41e-06	1.3e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	2.41e-06	1.3e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	2.41e-06	1.3e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	2.41e-06	1.3e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	2.37e-06	1.28e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	2.34e-06	1.26e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	2.3e-06	1.24e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	2.3e-06	1.24e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PTEN—pancreatic cancer	2.27e-06	1.22e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	2.26e-06	1.22e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—PIK3CA—pancreatic cancer	2.25e-06	1.21e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	2.25e-06	1.21e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—PIK3CA—pancreatic cancer	2.25e-06	1.21e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	2.24e-06	1.21e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—PIK3CA—pancreatic cancer	2.24e-06	1.21e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	2.24e-06	1.2e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—AKT1—pancreatic cancer	2.23e-06	1.2e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TP53—pancreatic cancer	2.22e-06	1.2e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—PIK3CA—pancreatic cancer	2.22e-06	1.19e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	2.21e-06	1.19e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	2.21e-06	1.19e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—AKT1—pancreatic cancer	2.19e-06	1.18e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TP53—pancreatic cancer	2.19e-06	1.18e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TP53—pancreatic cancer	2.18e-06	1.17e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TP53—pancreatic cancer	2.17e-06	1.17e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TP53—pancreatic cancer	2.17e-06	1.17e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PPARG—pancreatic cancer	2.16e-06	1.17e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TP53—pancreatic cancer	2.15e-06	1.16e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	2.14e-06	1.15e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	2.14e-06	1.15e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	2.13e-06	1.14e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—HRAS—pancreatic cancer	2.12e-06	1.14e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	2.09e-06	1.13e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—HRAS—pancreatic cancer	2.09e-06	1.12e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—HRAS—pancreatic cancer	2.08e-06	1.12e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—HRAS—pancreatic cancer	2.07e-06	1.12e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	2.07e-06	1.11e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	2.06e-06	1.11e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—HRAS—pancreatic cancer	2.05e-06	1.11e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	2.05e-06	1.1e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	2.03e-06	1.1e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—AKT1—pancreatic cancer	2.01e-06	1.08e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	1.99e-06	1.07e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.97e-06	1.06e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	1.9e-06	1.02e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—AKT1—pancreatic cancer	1.88e-06	1.01e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	1.85e-06	9.94e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—AKT1—pancreatic cancer	1.84e-06	9.92e-06	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—AKT1—pancreatic cancer	1.84e-06	9.91e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—AKT1—pancreatic cancer	1.84e-06	9.89e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—AKT1—pancreatic cancer	1.83e-06	9.85e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—AKT1—pancreatic cancer	1.81e-06	9.76e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	1.81e-06	9.73e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.72e-06	9.25e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.7e-06	9.17e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3CA—pancreatic cancer	1.7e-06	9.15e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	1.68e-06	9.04e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	1.6e-06	8.63e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.48e-06	7.99e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—AKT1—pancreatic cancer	1.39e-06	7.48e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.31e-06	7.05e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.05e-06	5.64e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—AKT1—pancreatic cancer	8.56e-07	4.61e-06	CbGpPWpGaD
